News
ABUS
--
0.00%
--
Introducing Arbutus Biopharma (NASDAQ:ABUS), The Stock That Zoomed 167% In The Last Year
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders might be concerned after seeing the share price drop 18% in...
Simply Wall St. · 1d ago
Overview of the RNAi for Therapeutic Market Trends, Size, Growth, Porters, PESTEL, Analysis and Forecast By 2028
Apr 14, 2021 (Market Insight Reports) -- New Analysis Of RNAi for Therapeutic Market overview, spend analysis, imports, segmentation, key players and...
Market Insight Reports · 3d ago
Ebola Treatment Market, Application Analysis, Share, Regional Outlook, Competitive Strategies & Forecast up to 2026
Apr 13, 2021 (Market Insight Reports) -- Latest Ebola Treatment Market Analysis - 2021-2026 The report titled Global Ebola Treatment Market showcases an...
Market Insight Reports · 4d ago
Thinking about buying stock in Rigel Pharmaceuticals, Checkpoint Therapeutics, GT Biopharma, ICICI Bank, or Arbutus Biopharma?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIGL, CKPT, GTBP, IBN, and ABUS.
PR Newswire - PRF · 4d ago
Thinking about buying stock in Arbutus Biopharma, BrightSphere Investment Group, Commscope Holding, Gogo Inc, or Jaguar Health?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, BSIG, COMM, GOGO, and JAGX.
PR Newswire - PRF · 04/08 12:35
RNA Therapy Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, April 08, Apr 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/08 11:52
4 Penny Stocks To Buy Now With Price Targets Up To 302%
Apr 02, 2021 (Penny Stocks via COMTEX) -- Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year....
Penny Stocks · 04/02 20:09
8-K: Arbutus Biopharma Corp
(EDGAR Online via COMTEX) -- 0001447028 False 0001447028 2021-04-01 2021-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/01 16:34
H.C. Wainwright Keeps a Buy Rating on Arbutus Biopharma (ABUS)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $10.00. The company's shares closed
SmarterAnalyst · 04/01 15:35
Arbutus Biopharma Stocks Is Trading Higher On Pan-Coronavirus Research Pact
Benzinga · 04/01 14:08
Thinking about buying stock in Arbutus Biopharma, Aemetis, FuboTV, Rubius Therapeutics, or Lithium Americas Corp?
NEW YORK, April 1, 2021 /PRNewswire via COMTEX/ -- NEW YORK, April 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS,...
PR Newswire - PRF · 04/01 13:31
Arbutus shares rise after SARS-CoV-2 research deal
Arbutus Biopharma (ABUS), X-Chem and Proteros biostructures have entered into a research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease ((Mpro)).Arbutus shares
Seekingalpha · 04/01 12:22
FCEL, QS, NNDM and CHPT among premarket gainers
Sonoma Pharmaceuticals SNOA +28% on agreement with EMC pharma.Future FinTech Group FTFT +24% on acquiring bitcoin mining farm.AeroCentury (ACY) +22%.Jaguar Health JAGX +19% on FY results.P&F Industries (PFIN) +21%.AgEagle Aerial Systems UAVS +19% on FY res...
Seekingalpha · 04/01 12:20
DJ Arbutus Biopharma in Pan-Coronavirus Discovery Research, Licensing Deal
Dow Jones · 04/01 12:09
BRIEF-Arbutus Biopharma Corp Says Co, X-Chem And Proteros Biostructures Enter A Pan-Coronavirus Discovery Research And License Agreement
reuters.com · 04/01 11:35
Arbutus Biopharma, X-Chem And Proteros Biostructures Enter Pan-Coronavirus Discovery Research And License Agreement; Financial Details Not Disclosed
Arbutus Biopharma Corporation (NASDAQ:ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the
Benzinga · 04/01 11:34
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks
GlobeNewswire · 04/01 11:30
Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)
SmarterAnalyst · 03/18 12:03
Biodefense Market Size, Share to Witness Remunerative Growth During 2020-2025 Live Now
Mar 17, 2021 (Market Insight Reports) -- Selbyville, Delaware According to the recent research report titled 'Global Biodefense Market - Analysis by Service,...
Market Insight Reports · 03/17 10:12
Arbutus Biopharma (ABUS) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $10.00. The company's shares closed
SmarterAnalyst · 03/16 16:55
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.